<DOC>
	<DOCNO>NCT00004794</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety efficacy intravenous cidofovir patient small peripheral cytomegalovirus retinitis . II . Obtain safety efficacy data relate different dosage cidofovir .</brief_summary>
	<brief_title>Phase II Randomized Study Cidofovir Peripheral Cytomegalovirus Retinitis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . Cidofovir administer intravenously . Treatment ideally begin within 24 hour randomization . In first group , therapy defer disease progression . Patients treat accord best medical judgement , include option cidofovir therapy . The second group receive induction cidofovir every 7 day 2 week , begin maintenance low dose give every 14 day dose-limiting toxicity disease progression occur . The third group receive cidofovir induction follow high maintenance dose give every 14 day dose-limiting toxicity disease progression occur . Probenecid intravenous hydration administer concurrently cidofovir . Patients follow progression survival every 2 week 23 week , every 12 week . At disease progression , patient may re-treated another course induction maintenance .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Acquired immunodeficiency syndrome ( AIDS ) Meets Centers Disease Control Prevention definition Peripheral cytomegalovirus ( CMV ) retinitis Diagnosed ophthalmologist certify Study Ocular Complications AIDS group At least 1 lesion measure least 25 % disc photograph No lesion within zone 1 No lesion involve 25 % retina regardless location Visual acuity affect eye 3 line Early Treatment Diabetic Retinopathy Study chart 1 meter Snellen equivalent 8/200 No retinal detachment affect eye No medium opacity preclude visualization fundus eye No extraocular CMV disease Prior/Concurrent Therapy No prior concurrent antiCMV therapy , i.e . : Ganciclovir Foscarnet CMV hyperimmune immunoglobulin Other investigational agent antiCMV activity Prior CMV prophylaxis allow At least 7 day since nephrotoxic drug , include : Amphotericin B Vidarabine Aminoglycoside antibiotic Intravenous pentamidine Patient Characteristics Age : 13 60 Performance status : Karnofsky 60 % 100 % Hematopoietic : ANC least 750 Platelets least 50,000 Hemoglobin great 7.5 g/dL Hepatic : Bilirubin great 3.0 mg/dL Transaminases great 5 time normal Renal : Creatinine great 1.5 mg/dL Proteinuria le 1+ No clinically significant renal disease No dialysis Cardiovascular : No clinically significant cardiac disease , include : Ischemia Congestive heart failure Arrhythmia Other : No probenecid allergy No medical problem sufficient hinder compliance therapy follow , include drug alcohol abuse No pregnant nursing woman Negative serum pregnancy test require fertile woman Adequate birth control require fertile patient 3 month study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 1998</verification_date>
	<keyword>cytomegalovirus retinitis</keyword>
	<keyword>ophthalmologic disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>